These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 23960422)
1. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. Chadda RK; Ramshankar P; Deb KS; Sood M J Pharmacol Pharmacother; 2013 Jul; 4(3):176-86. PubMed ID: 23960422 [TBL] [Abstract][Full Text] [Related]
2. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090 [TBL] [Abstract][Full Text] [Related]
3. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188 [TBL] [Abstract][Full Text] [Related]
4. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Vuk A; Kuzman MR; Baretic M; Osvatic MM Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569 [TBL] [Abstract][Full Text] [Related]
5. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790 [TBL] [Abstract][Full Text] [Related]
9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
10. Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. Bartoli F; Crocamo C; Clerici M; Carrà G Eur Neuropsychopharmacol; 2015 Oct; 25(10):1767-74. PubMed ID: 26164075 [TBL] [Abstract][Full Text] [Related]
11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441 [TBL] [Abstract][Full Text] [Related]
14. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Sneller MH; de Boer N; Everaars S; Schuurmans M; Guloksuz S; Cahn W; Luykx JJ Front Psychiatry; 2021; 12():625935. PubMed ID: 33868046 [No Abstract] [Full Text] [Related]
15. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068 [TBL] [Abstract][Full Text] [Related]
17. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Gautam S; Meena PS Indian J Psychiatry; 2011 Apr; 53(2):128-33. PubMed ID: 21772644 [TBL] [Abstract][Full Text] [Related]
18. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
19. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512 [TBL] [Abstract][Full Text] [Related]
20. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Nielsen J; Skadhede S; Correll CU Neuropsychopharmacology; 2010 Aug; 35(9):1997-2004. PubMed ID: 20520598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]